Fig. 3
Response rates at weeks 9–12. All: total patient population; HFEM: patients with high-frequency episodic migraine; CM: patients with chronic migraine. ≥ 50% responders: proportion of patients with a ≥ 50% reduction in monthly migraine/headache days compared to baseline; ≥ 75% responders: proportion of patients with a ≥ 75% reduction in monthly migraine/headache days compared to baseline; 100% responders: proportion of patients with a 100% reduction in monthly migraine/headache days compared to baseline